Skip to content
type1.science

MiniMed Vivera (next-generation SmartGuard algorithm)

MiniMed

The right ambition. Almost none of the evidence yet.

MiniMed's next-generation control algorithm — the company's first serious move toward a fully closed loop. Vivera is designed to make the meal bolus *optional*: it can detect and dose for a meal on its own, take a simple meal announcement, or accept a traditional carb count. It was unveiled in March 2026 on a small feasibility study (14 adults and 13 children over three months) and no time-in-range results have been published. Its two head-to-head pivotal trials moved unevenly: NEXUS began recruiting in July 2026, while ELEVATE has not started. A software update delivering Vivera to existing 780G and Flex is reported for 2027 — by a conference recap, not by MiniMed. It is not cleared anywhere.

On the horizonEarly evidenceaidhybrid-closed-loopfully-closed-loop-frontierminimedsmartguard

The scorecard

Time in range55

No time-in-range results have been published for Vivera in type 1 diabetes at all. The feasibility study was 27 people over three months, and the registered trials are powered for *non-inferiority* in time in range (70–180 mg/dL / 3.9–10.0 mmol/L) against the system the person is already using — so the honest expectation is parity with less burden, not a higher ceiling.[2]

Hypo protection60

Vivera inherits SmartGuard's predictive low management, which has a good track record on the 780G, but no Vivera-specific time-below-range or severe-hypoglycemia data has been published. An algorithm that doses for meals it detects itself has to be judged on its own lows, not its predecessor's.[1]

Automation level85

The defining claim, and a real one: meal bolusing becomes optional, with automatic detection and dosing of unannounced meals. No other major manufacturer has committed to shipping that to an installed base. Scored below the fully-closed-loop research frontier because Vivera's version has only been shown in a 27-person feasibility study with no published outcomes.[1]

Freedom (form factor)62

Vivera is software, so its wearability is whatever it runs on: the tubed 780G and the tubed, screenless, phone-controlled MiniMed Flex. Control therefore depends on the host pump; Vivera itself adds meal automation, not phone control. The tubeless MiniMed Fit is a separate, later programme.[5]

Average glucose55

No mean glucose, GMI or HbA1c results have been published. The only public efficacy datum is a single anecdote — one 13-year-old reported going from 8% to 6.7% HbA1c — which is not evidence of anything at population level.[1]

Low variability55

Machine-learning adaptation plus automatic meal dosing is exactly the recipe for flatter post-meal curves, and that is the point of the design — but it is untested at scale and nothing has been published.[1]

Exercise handling50

No Vivera-specific exercise data. Unannounced activity is the hardest remaining problem for any algorithm that is also dosing for meals it detected itself, so this is scored cautiously until results exist.

Customizability60

Three meal-handling modes — no bolus, a simple announcement, or a full carb count — is genuine user choice, and more than most systems offer. But it remains a closed MiniMed ecosystem with no access to the algorithm's internals.[1]

Access & cost25

Not cleared by any regulator, not available anywhere, and not yet reachable under the Vivera name. The NEXUS NMX8 trial began recruiting in July 2026, but the registry never calls the system Vivera; the 2027 software-update date remains a conference report, not a MiniMed commitment.[3]

Glycemic criteria are scored on the levels actually achieved in large real-world Type 1 diabetes cohorts — not the headline improvement over a trial's baseline (an improvement that looks bigger when the starting population was doing poorly). Type 2 diabetes trial data is never used to score a Type 1 system; where only improvement data exists, it informs the rationale, not the score. Freedom captures form factor and wearability, so a tubeless system is rewarded for the mobility a tubed one can't match.

Editor’s take

Vivera is the most important thing a large pump manufacturer has said out loud in years: the meal bolus should be optional. That is the burden people with type 1 diabetes actually carry every day, and MiniMed is the first of the big companies to promise to lift it for an installed base rather than for a research cohort. We want this to work. But look at what exists in August 2026 — an ATTD presentation, 27 people, three months, zero published time-in-range numbers, and one head-to-head trial newly recruiting and another not yet started. And read the endpoints: both registered trials are powered for *non-inferiority*, meaning the bar MiniMed has set itself is "no worse than what you already have, with less work". That is an honest and worthwhile bar — the prize here is burden, not a higher ceiling — but it is not the same thing as a fully closed loop that beats a hybrid one. Judge this record again when the first per-arm outcomes land.

The full picture

Every automated insulin delivery system on sale today is a hybrid closed loop: the algorithm runs your background insulin and fires corrections, but you still have to announce every meal. Vivera is MiniMed's answer to that — a third-generation control algorithm, using machine learning to adapt to the individual, in which the meal bolus becomes optional. You can let it detect the meal and dose for it, give it a simple "I'm eating" announcement, or carry on counting carbs exactly as you do now.1

It is software, not hardware. It is designed to run on pumps MiniMed already sells — the 780G and the newer screenless, phone-controlled MiniMed Flex — which is what makes it different from every other fully-closed-loop effort. Most of those are research systems reaching dozens of people. This one is aimed at an installed base of hundreds of thousands.

What has actually been shown

Very little, and it is important to be blunt about that.

Vivera was unveiled on 12 March 2026 at the ATTD conference in Barcelona. The evidence behind the unveiling was a feasibility study of 14 adults and 13 children over three months. No time-in-range results have been published from it. No mean glucose, no HbA1c, no time-below-range. The single public efficacy datum in the coverage is an anecdote — one 13-year-old reported going from an HbA1c of 8% to 6.7%.1

You may see figures circulating in secondary coverage claiming roughly 74% time in range without meal announcement and 82% with. We have not been able to trace those to any primary source, so we do not publish them and neither should anyone else.

The trials — and what they are really testing

The registries are the clearest window on where this programme stands, with one important caveat: no registry record uses the name "Vivera". They all call the system the MiniMed NMX8 or the "Novel Medtronic Experimental AID System". The Vivera↔NMX8 link comes from press and manufacturer communication, not from ClinicalTrials.gov.

  • GATEWAY (NCT07228117) — the one actually running. Recruiting since February 2026, 400 people across the US, Australia and New Zealand, randomised to no meal bolus, bolus at all meals, or bolus at will, for about 90 days. Its primary outcomes are descriptive — per-arm time in range (70–180 mg/dL / 3.9–10.0 mmol/L) and time below 70 mg/dL (3.9 mmol/L) — with primary completion in January 2027.2 It is registered against the NMX8 hardware that ships as MiniMed Flex, so it appears on this site under MiniMed Flex too. Its meal-bolus arms are the closest thing to a public test of the meal-optional idea.
  • NEXUS (NCT07227805) — the experimental algorithm head-to-head against the 780G over 12 weeks, 116 people aged 2 and up with type 1 or type 2 diabetes. It began recruiting after an actual start on 19 July 2026, and now estimates completion on 17 March 2027.3
  • ELEVATE (NCT07401901) — 230 adults with type 1 diabetes who are already on a commercial AID system with an HbA1c of 7.5% or above, across 21 sites in France, Germany, Italy, the Netherlands, Spain and the UK. It remained not yet recruiting on 8 August 2026, with a planned 15 October 2026 start, primary completion in December 2027, and final completion in March 2028.4

Read the endpoints carefully, because they set the honest expectation. Both NEXUS and ELEVATE are powered for non-inferiority in time in range — the question they ask is "is Vivera no worse than the loop you already use?", not "is it better?". That is a defensible design: the thing being won here is the removal of carb counting, and matching your current control while doing far less work would be a genuine win. But it means nobody should expect a headline jump in time in range from this programme.

Why the ambition matters anyway

The reason meal announcement has survived is not laziness of design — it is the speed of injected insulin. Insulin under the skin peaks 1.5–2 hours after it is dosed, while a meal hits the bloodstream in 30–60 minutes. An algorithm that only reacts once it sees glucose rising is starting the race late. That is why the fully-closed-loop research literature reports meal-detection latencies of 25–40 minutes and post-meal excursions that automation alone cannot fully catch.

Vivera does not repeal that physics. What it does is make the compromise a choice rather than a requirement — bolus when you can be bothered, don't when you can't, and let the algorithm cover the gap. For a lot of people that trade will be worth several points of time in range. It is also the first time a major manufacturer has committed to putting that choice in the hands of people who already own the pump.

What to watch

A software update delivering Vivera to existing 780G and MiniMed Flex users is reported for 2027 — but the source is a community recap of ADA 2026, not MiniMed.5 MiniMed has published no regulatory submission date and no launch timeline of its own. NEXUS recruiting is real progress, but the registry calls the device NMX8 rather than Vivera; until GATEWAY's meal-arm data or NEXUS results appear, the meal-optional claim still rests on a very small feasibility study.

References

  1. MiniMed unveils Vivera: a next-generation fully-closed-loop algorithm — coverage of the ATTD 2026 unveiling, 12 March 2026. Feasibility study: 14 adults and 13 children, three months. No time-in-range figures reported. ↩ ↩2

  2. GATEWAY — Safety Evaluation of the MiniMed NMX8-AID System in Children and Adults Living With Diabetes. NCT07228117, recruiting since 2 February 2026, n=400, primary completion January 2027. https://clinicaltrials.gov/study/NCT07228117 ↩

  3. NEXUS — Evaluation of the Safety and Performance of the Novel Medtronic Experimental AID System (NMX8) in People Living With Diabetes. NCT07227805, recruiting after actual start 19 July 2026, n=116, versus the MiniMed 780G, completion estimated 17 March 2027; registry updated 29 July 2026. https://clinicaltrials.gov/study/NCT07227805 ↩

  4. ELEVATE — Evaluation of the Safety and Effectiveness of the Novel Medtronic Experimental AID System (NMX8) in Adults Living With Type 1 Diabetes. NCT07401901, not yet recruiting on 8 August 2026, planned start 15 October 2026, n=230, 21 sites across France, Germany, Italy, the Netherlands, Spain and the UK, primary completion 4 December 2027 and study completion 29 March 2028. https://clinicaltrials.gov/study/NCT07401901 ↩

  5. Closed-loop updates from ADA 2026 — community conference recap (not a MiniMed announcement); sole source for the reported 2027 software update to the 780G and MiniMed Flex. ↩

Coming soon

ETA · Investigational. NEXUS (NCT07227805, n=116, versus the 780G) is recruiting after starting 19 July 2026, with completion estimated March 2027. ELEVATE (NCT07401901, n=230, six European countries including the UK) remains planned for October 2026 through March 2028. A 780G/Flex software update is reported for 2027 in an ADA recap; MiniMed has announced neither a regulatory-submission nor launch date.

  • →NEXUS (NCT07227805) — MiniMed's experimental algorithm versus the 780G over 12 weeks, n=116, non-inferiority in time in range · recruiting; started 19 July 2026, completion estimated 17 March 2027
  • →ELEVATE (NCT07401901) — n=230 adults with type 1 diabetes already on a commercial AID system with HbA1c ≥7.5%, 21 sites across six European countries including the UK, non-inferiority in time in range versus their existing system · not yet recruiting; planned start October 2026, primary completion December 2027, study completion March 2028
  • →GATEWAY (NCT07228117) — the study actually running: 400 people randomised to no meal bolus, bolus at all meals, or bolus at will, with descriptive per-arm outcomes · recruiting since February 2026; primary completion January 2027
  • →Software update delivering Vivera to existing MiniMed 780G and MiniMed Flex users (reported at ADA 2026, not confirmed by MiniMed) · reported for 2027

Sources

  1. [1]MiniMed unveils Vivera: a next-generation fully-closed-loop algorithm · news · 2026-03-12 — Unveiling coverage from ATTD 2026. Feasibility study = 14 adults and 13 children over three months. No time-in-range figures are given anywhere in the piece; the only efficacy datum is a single anecdote (a 13-year-old going from 8% to 6.7% HbA1c).
  2. [2]ELEVATE — Evaluation of the Safety and Effectiveness of the Novel Medtronic Experimental AID System (NMX8) in Adults Living With Type 1 Diabetes · registry — NCT07401901. Not yet recruiting as of 8 August 2026; planned start 15 October 2026, primary completion 4 December 2027 and study completion 29 March 2028. n=230, 21 sites across six European countries including the UK, adults with type 1 diabetes already on a commercial AID with HbA1c ≥7.5%. Primary endpoint is non-inferiority in time in range (70–180 mg/dL / 3.9–10.0 mmol/L) versus their existing system. The registry record does not use the name "Vivera".
  3. [3]NEXUS — Evaluation of the Safety and Performance of the Novel Medtronic Experimental AID System (NMX8) in People Living With Diabetes · registry — NCT07227805. Recruiting after an actual start on 19 July 2026; n=116, 12 weeks, versus the MiniMed 780G, enrolling people aged 2+ with type 1 or type 2 diabetes. Completion is estimated 17 March 2027. The registry record does not use the name "Vivera".
  4. [4]GATEWAY — Safety Evaluation of the MiniMed NMX8-AID System in Children and Adults Living With Diabetes · registry · 2026-06-08 — NCT07228117. Recruiting since 2 February 2026, n=400, US/Australia/New Zealand, primary completion January 2027. Randomises participants to no meal bolus, bolus at all meals, or bolus at will; primary outcomes are descriptive per-arm time in range and time below 70 mg/dL (3.9 mmol/L). The registry names the system NMX8-AID, not Vivera.
  5. [5]Closed-loop updates from ADA 2026 · community · 2026-06-25 — Community conference recap, not a MiniMed announcement. Sole source for the reported 2027 software update to the 780G and MiniMed Flex, so that timing is attributed rather than stated as fact.